CD4 and metastatic malignant neoplasm: Development of MH2 vaccines is a promising approach for the prevention and treatment of patients with metastatic cancers.42 The MH2 vaccines are tumor cells that are genetically modified to express MH2 and co-stimulatory molecules and are capable to activate tumor-reactive CD4+ T lymphocytes.